UBS Group’s Amedisys AMED Stock Holding History

UBS Group’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-21,700	Closed	-$1.21M	–	7820
2017 Q3	$1.21M	Buy	+21,700	New	+$1.15M	﹤0.01%	3545
2015 Q1	–	Sell	-400	Closed	-$12K	–	8751
2014 Q4	$12K	Buy	+400	New	+$9.88K	﹤0.01%	8204

Other funds holding AMED

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

MCI

MRP Capital Investments Alpharetta, Georgia $136M AUM 59.34% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

UBS Group's AMED Position: Q3 2025 in Review

UBS Group sold out of Amedisys (AMED) in Q3 2025, closing a stake of 878,850 shares — an estimated $86.5M sold.

UBS Group first reported a position in AMED in Q4 2014 and held it in 43 quarters. The position peaked at $86.5M in Q2 2025. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

UBS Group reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
UBS Group sold 878,850 Amedisys shares in Q3 2025, an estimated $86.5M.
UBS Group first reported a position in Amedisys in Q4 2014 and held it in 43 quarters.
UBS Group's Amedisys position peaked at $86.5M in Q2 2025.
4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.